Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical studies with chemokine receptor-5 (CCR5)-inhibitors

Clinical studies with chemokine receptor-5 (CCR5)-inhibitors REVIEW URRENT Clinical studies with chemokine receptor-5 (CCR5)- PINION inhibitors a b,c Christoph Boesecke and Sarah L. Pett Purpose of review To summarise recently published clinical studies of chemokine receptor-5 (CCR5)-blockers, including the small-molecule blocker, maraviroc (MVC) and CCR5-monoclonal antibodies for HIV. MVC may have immunomodulating properties through CCR5-blockade. MVC appears well tolerated and penetrates the central nervous system. For these reasons, MVC is being investigated in immunodiscordance, prevention of IRIS and in HCV-HIV co-infection. Novel techniques allow tropism assignment via sequencing of proviral DNA; this testing platform is being utilised in MVC switch studies in those with HIV viraemia below the level of quantification. MVC is being utilised in regimen intensification studies for HIV associated neurocognitive disease. Recent findings MVC has no anti-inflammatory activity in rheumatoid arthritis. MVC appears well tolerated in hepatitis virus co-infected patients and MVC-intensification in HCV–HIV co-infection suggests a favourable impact on liver fibrosis. Early pilot data suggests MVC intensification may have functional benefit in the CNS. There is a growing body of data on tropism testing using proviral DNA; this technology is being utilised in MVC switch studies. CCR5-monoclonal antibodies administered subcutaneously are promising in Phase II development. Summary The place of MVC http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Clinical studies with chemokine receptor-5 (CCR5)-inhibitors

Current Opinion in HIV and Aids , Volume 7 (5) – Sep 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/clinical-studies-with-chemokine-receptor-5-ccr5-inhibitors-OMa7cVovYA

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e328356e933
pmid
22832708
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT Clinical studies with chemokine receptor-5 (CCR5)- PINION inhibitors a b,c Christoph Boesecke and Sarah L. Pett Purpose of review To summarise recently published clinical studies of chemokine receptor-5 (CCR5)-blockers, including the small-molecule blocker, maraviroc (MVC) and CCR5-monoclonal antibodies for HIV. MVC may have immunomodulating properties through CCR5-blockade. MVC appears well tolerated and penetrates the central nervous system. For these reasons, MVC is being investigated in immunodiscordance, prevention of IRIS and in HCV-HIV co-infection. Novel techniques allow tropism assignment via sequencing of proviral DNA; this testing platform is being utilised in MVC switch studies in those with HIV viraemia below the level of quantification. MVC is being utilised in regimen intensification studies for HIV associated neurocognitive disease. Recent findings MVC has no anti-inflammatory activity in rheumatoid arthritis. MVC appears well tolerated in hepatitis virus co-infected patients and MVC-intensification in HCV–HIV co-infection suggests a favourable impact on liver fibrosis. Early pilot data suggests MVC intensification may have functional benefit in the CNS. There is a growing body of data on tropism testing using proviral DNA; this technology is being utilised in MVC switch studies. CCR5-monoclonal antibodies administered subcutaneously are promising in Phase II development. Summary The place of MVC

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Sep 1, 2012

There are no references for this article.